[A18-49] Emicizumab (haemophilia A) - Addendum to Commission A18-20

Last updated 20.09.2018

Project no.:
A18-49

Commission:
Commission awarded on 06.08.2018 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Haematology

Indication/Intervention:

Routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors

Result of dossier assessment:

Conclusion of dossier assessment A18-20 unchanged

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2018-09-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.